Latest From Zydus Cadila
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
Cadila is exploring orphan indications for saroglitazar magnesium, in addition to the approaching Phase III NASH clinical trials for its lead NCE. Meanwhile, it counts on new product launches and biosimilars to take its FY21 growth story ahead.
Deal news from GeoVax/BravoVax, Onconova/HanX, Zydus Cadila/China Medical System Holdings, EyePoint/Ocumension, Ningbo NewBay Medical/Genentech, Otsuka/PhoreMost, Almirall/WuXi Biologics
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
- Generic Drugs
- OTC, Consumer
- Therapeutic Areas
- Parent & Subsidiaries
- Zydus Cadila
- Senior Management
- Pankaj R Patel, Chmn. & Managing Dir.
- Contact Info
Phone: (91) 79 26868100
Zydus Tower, Satellite Cross Roads
Ahmedabad , 380015
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.